1530.HK - 3SBio Inc.

HKSE - HKSE Delayed Price. Currency in HKD
15.520
+0.140 (+0.91%)
At close: 4:08PM HKT
Stock chart is not supported by your current browser
Previous Close15.380
Open15.400
Bid15.420 x 0
Ask15.520 x 0
Day's Range15.180 - 15.580
52 Week Range8.210 - 23.250
Volume4,744,671
Avg. Volume8,707,105
Market Cap39.327B
Beta (3Y Monthly)1.18
PE Ratio (TTM)34.99
EPS (TTM)0.444
Earnings DateMar 25, 2019 - Mar 29, 2019
Forward Dividend & Yield0.07 (0.44%)
Ex-Dividend Date2018-06-29
1y Target Est18.68
  • PR Newswirelast month

    3SBio Unveils 2018 Annual Results: Revenue Soars by 22.7%, Normalized Net Profit Soars by 29.0%, R&D Expenses Jumps Over 40%

    HONG KONG, March 21, 2019 /PRNewswire/ -- Chinese leading biotechnology company 3SBio (01530.HK) today released its 2018 annual results, showing that the Company has been posting dramatic business growth, and has been gearing up R&D layout and investment in innovative drugs. As of December 31, 2018, amongst the 32 product candidates within the Company's active pipeline, 22 were being developed as National Class I New Drugs in China, including 11 in oncology, 12 in immunology, 6 in nephrology, 2 in metabolic diseases and 1 in dermatology. After reaching separate partnerships with Japan's Toray and US-based Refuge Biotechnologies in 2018,the Company also announced partnerships with Samsung Bioepis, Verseau and TLC as part of efforts to enrich its existing product portfolio and pipeline at the beginning of 2019.

  • PR Newswire2 months ago

    3SBio and TLC Form Exclusive Partnership to Commercialize Two NanoX™ Products in Mainland China

    SHENYANG, China, March 3, 2019 /PRNewswire/ -- 3SBio Inc. ("3SBio") (1530.HK) and Taiwan Liposome Company, Ltd. ("TLC") (Nasdaq: TLC, TWO: 4152) today announced an exclusive partnership to commercialize in mainland China two liposomal products utilizing TLC's proprietary NanoX™ technology platform in the therapeutic areas of oncology and severe infectious diseases. Under this alliance, TLC and 3SBio will cooperate to obtain regulatory approvals in mainland China, and TLC will utilize its commercial-scale manufacturing capabilities to supply the two liposomal products for 3SBio to commercialize in mainland China.  The two companies also agreed to further collaboration in researching and developing other novel liposomal products in the therapeutic areas of osteoarthritis, pain management, ophthalmology, and oncology.

  • PR Newswire2 months ago

    3SBio and TLC Form Exclusive Partnership to Commercialize Two NanoX(TM) Products in Mainland China

    SHENYANG, China, March 4, 2019 /PRNewswire/ -- 3SBio Inc. ("3SBio") (1530.HK) and Taiwan Liposome Company, Ltd. ("TLC") (Nasdaq: TLC, TWO: 4152) today announced an exclusive partnership to commercialize in mainland China two liposomal products utilizing TLC's proprietary NanoX™ technology platform in the therapeutic areas of oncology and severe infectious diseases. Under this alliance, TLC and 3SBio will cooperate to obtain regulatory approvals in mainland China, and TLC will utilize its commercial-scale manufacturing capabilities to supply the two liposomal products for 3SBio to commercialize in mainland China.  The two companies also agreed to further collaboration in researching and developing other novel liposomal products in the therapeutic areas of osteoarthritis, pain management, ophthalmology, and oncology.

  • PR Newswire2 months ago

    3SBio and Verseau Establish Global Clinical Development Collaboration for First-in-class Immuno-Oncology Therapies

    SHENYANG, China and BOSTON, Feb. 11, 2019 /PRNewswire/ -- 3SBio Inc. ("3SBio") (1530.HK) and Verseau Therapeutics, Inc. ("Verseau") announced today a partnership agreement focused on the development and commercialization of novel monoclonal antibodies in the field of immuno-oncology for a broad range of cancers. Verseau's proprietary drug discovery platform generates first-in-class macrophage checkpoint modulators (MCMs) to benefit patients with cancer, immune and inflammatory diseases. Under the terms of the agreement, 3SBio will receive an exclusive license to develop and commercialize a select number of MCM antibodies for all human oncology indications in Greater China, including mainland China, Taiwan, Hong Kong and Macau ("Territory").

  • Reuters3 months ago

    BRIEF-Samsung Biologics’ JV Samsung Bioepis Partners With Chinese Biopharma 3SBio

    Jan 7 (Reuters) - Samsung Bioepis, a joint venture between Samsung BioLogics and Biogen, in a press release: * SAYS FORMS PARTNERSHIP WITH CHINESE BIOPHARMA 3SBIO Further company coverage:

  • PR Newswire3 months ago

    3SBio and Samsung Bioepis enter biosimilar collaboration agreement

    SHENYANG, China , Jan. 6, 2019 /PRNewswire/ -- Chinese leading Biopharmaceu ti cal company 3SBio Inc. (01530.HK)(" 3SBio ") announced today that it has entered into a collaboration agreement ...

  • How Do Analysts See 3SBio Inc (HKG:1530) Performing In The Next Couple Of Years?
    Simply Wall St.10 months ago

    How Do Analysts See 3SBio Inc (HKG:1530) Performing In The Next Couple Of Years?

    3SBio Inc’s (HKG:1530) released its most recent earnings update in December 2017, which confirmed that the company gained from a strong tailwind, leading to a double-digit earnings growth of 31.27%.Read More...

  • Little Known China Biotech Firm Lures Top Global Stock Fund
    Bloomberglast year

    Little Known China Biotech Firm Lures Top Global Stock Fund

    3SBio Inc., a Chinese biotech company that’s seen its revenue double in past two years, recently caught the eye of one of the world’s best performing global funds. Dynamic Power Global Growth Class -- the top performer among the 1,000 mutual funds investing globally in the past five years -- bought 17.4 million Hong Kong-listed shares of 3SBio a few months ago, making it the only Chinese healthcare stock in its $1.2 billion portfolio. “I’m always looking for companies where there is not only growth, but the ability to sustain that growth,” Noah Blackstein, the 48-old Canadian fund manager said in an interview last month when asked why Dynamic Power allocated about one third of its capital to Chinese stocks including 3SBio.